肝豆状核变性、非酒精性脂肪性肝病和自身免疫性肝炎儿童肝组织超微结构变化特征*

doi:10.3969/j.issn.1672-5069.2023.03.016

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (3): 364-367.doi: 10.3969/j.issn.1672-5069.2023.03.016

肝豆状核变性、非酒精性脂肪性肝病和自身免疫性肝炎儿童肝组织超微结构变化特征^*

黄慧, 林敏, 曾桂香

330000 南昌市南昌医学院附属儿童医院/江西省儿童医院病理科(黄慧,林敏);解放军联勤保障部队第九○三医院儿科(曾桂香)

收稿日期:2023-03-07 出版日期:2023-05-10 发布日期:2023-05-08
通讯作者: 曾桂香,E-mail:zeng12320222022@163.com
作者简介:黄慧,男,39岁,医学硕士,主治医师。研究方向:儿童分子遗传学研究。E-mail:enjoy8882005@163.com
基金资助:
^*江西省自然科学基金面上项目(编号:20212BAB206012)

Hepatic ultrastructural features of paediatric Wilson’s disease, NAFLD and autoimmune hepatitis

Huang Hui, Lin Min, Zeng Guixiang

Department of Pathology, Provincial Children's Hospital, Affiliated to Nanchang Medical College, Nanchang 330000,Jiangxi Province, China

Received:2023-03-07 Online:2023-05-10 Published:2023-05-08

摘要/Abstract

摘要： 目的分析比较肝豆状核变性(WD)、非酒精性脂肪性肝病(NAFLD)和自身免疫性肝炎(AIH)儿童肝组织超微结构变化特征。方法 2018年12月～2022年2月我院诊治的WD患儿37例、NAFLD患儿20例和AIH患儿17例,均接受超声引导下肝活检,行常规组织病理学和超微结构观察。结果 WD组肝纤维化和铜染色阳性占比分别为78.4%和29.7%,显著高于NAFLD组的10.0%和0.0%(P<0.05),而巨泡状脂肪变性和小脂滴比例分别为62.2%和75.7%,显著低于NAFLD组的95.0%和95.0%(P<0.05);WD组肝组织肝细胞核空泡样变比例为59.5%,显著高于AIH组的17.6%(P<0.05),而门脉炎症、界面性肝炎、小叶内炎症、浆细胞浸润(>30%)和肝细胞玫瑰花样结构比例分别为78.4%、10.8%、64.9%、5.4%和24.3%,显著低于AIH组的100.0%、88.2%、82.4%、64.7%和76.5%,差异均具有统计学意义(P<0.05);在超微结构方面,WD组线粒体多形性、嵴尖端扩张、膜复制和基质密度增高比例分别为81.1%、83.8%、62.2%和62.2%,显著高于NAFLD组的30.0%、15.0%、5.0%和5.0%(P<0.05)或AIH组的23.5%、11.8%、5.9%和5.9%(P<0.05),而夹杂准晶体比例为0.0%,显著低于NAFLD组的15.0%(P<0.05)。结论 WD、NAFLD和AIH患儿肝组织具有各自特征性的病理学变化,尤其是超微结构的特征变化可能有助于区分和鉴别诊断。

关键词: 肝豆状核变性, 非酒精性脂肪性肝病, 自身免疫性肝炎, 组织病理学, 超微结构

Abstract: Objective The purpose of this study was to investigate the ultrastructural changes of liver tissues in children with Wilson]s disease (WD), non-alcoholic fatty liver diseases (NAFLD) and autoimmune hepatitis (AIH). Methods 37 children with WD, 20 children with NAFLD and 17 children with AIH were encountered in our hospital between December 2018 and February 2022, and all children underwent liver biopsies for routine and ultrastructural examination. Results The proportion of liver fibrosis and copper staining positive in children with WD were 78.4% and 29.7%, significantly higher than 10.0% and 0.0%(P<0.05) in children with NAFLD, while the proportion of macrovesicular steatosis and lipid droplets were 62.2% and 75.7%, significantly lower than 95.0% and 95.0%(P<0.05)in children with NAFLD; the proportion of hepatocyte nucleus vacuolar degeneration in children with WD was 59.5%, much higher than 17.6%(P<0.05) in children with AIH, while the proportion of portal inflammation, interfacial hepatitis, lobular inflammation, plasma cell infiltration and hepatocyte rosette structure were 78.4%, 10.8%, 64.9%, 5.4% and 24.3%, significantly lower than 100.0%, 88.2%, 82.4%, 64.7% and 76.5% in children with AIH (P<0.05); as for the ultrastructural changes, the proportion of mitochondrial pleomorphism, crest tip dilatation, membrane replication and increased matrix density in children with WD were 81.1%, 83.8%, 62.2% and 62.2%, significantly higher than 30.0%, 15.0%, 5.0% and 5.0%(P<0.05) in children with NAFLD or 23.5%, 11.8%, 5.9% and 5.9%(P<0.05) in children with AIH, while the proportion of quasicrystal inclusion was 0.0%, much lower than 15.0%(P<0.05) in children with NAFLD. Conclusion The liver histo-pathological changes, including ultrastructural features, in children with WD, NAFLD and AIH are specific, which could provide evidences for diagnosis of them.

Key words: Wilson’s disease, Non-alcoholic fatty liver diseases, Autoimmune hepatitis, Liver histo-pathology, Ultrastructure

黄慧, 林敏, 曾桂香. 肝豆状核变性、非酒精性脂肪性肝病和自身免疫性肝炎儿童肝组织超微结构变化特征^*[J]. 实用肝脏病杂志, 2023, 26(3): 364-367.

Huang Hui, Lin Min, Zeng Guixiang. Hepatic ultrastructural features of paediatric Wilson’s disease, NAFLD and autoimmune hepatitis[J]. Journal of Practical Hepatology, 2023, 26(3): 364-367.

参考文献

[1] Ferenci P, Stremmel W, Czlonkowska A, et al. Age and sex but not atp7b genotype effectively influence the clinical phenotype of Wilson disease. Hepatology, 2019,69(4): 1464-1476.
[2] Sintusek P, Kyrana E, Dhawan A. Value of serum zinc in diagnosing and assessing severity of liver disease in children with Wilson disease. J Pediatr Gastroenterol Nutr, 2018, 67(3): 377-382.
[3] Javaid HW, Munir F, Bahram S. Relapsing extramedullary multiple myeloma presenting as acute liver failure. Cureus, 2021, 13(12): e20786.
[4] Gronbaek L, Otete H, Ban L, et al.Incidence, prevalence and mortality of autoimmune hepatitis in England 1997-2015. a population-based cohort study. Liver Int, 2020, 40(7): 1634-1644.
[5] Gerosa C, Fanni D, Congiu T, et al. Liver pathology in wilson's disease: from copper overload to cirrhosis. J Inorg Biochem, 2019, 193: 106-111.
[6] Ruchika T, Madhukar M, Abhishek KG.External capsular hyperintensities in Wilson's disease presenting with refractory status epilepticus. Neurol India, 2022, 70(6): 2446-2448.
[7] Camarata MA, Ala A, Coskun AK, et al. Major depressive disorder in an international multisite Wilson disease registry. J Acad Consult Liaison Psych, 2022,45(2):145-149.
[8] Bhandari G, Tiwari V, Gupta A, et al. IgA nephropathy with Wilson's disease: a case report and literature review. Indian J Nephrol, 2021, 31(5): 474-477.
[9] Balijepalli C, Yan K, Gullapalli L, et al.Quality of life in Wilson's disease: a systematic literature review. J Health Econ Outcomes Res, 2021, 8(2): 105-113.
[10] Zhou XX, Pu XY, Xiao X, et al. Observation on the changes of clinical symptoms, blood and brain copper deposition in Wilson disease patients treated with dimercaptosuccinic acid for 2 years. J Clin Neurosci, 2020, 81: 448-454.
[11] Jing XZ, Li GY, Wu YP, et al. Free water imaging as a novel biomarker in Wilson's disease: a cross-sectional study. Parkinsonism Relat Disord, 2023, 106: 105234.
[12] Brandi G, Rizzo A, Deserti M, et al. Wilson disease, abcc2 c.3972c> t polymorphism and primary liver cancers: suggestions from a familial cluster. BMC Med Genet, 2020, 21(1): 225.
[13] Zhu L, Yin H, Wang Y, et al.Disrupted topological organization of the motor execution network in Wilson's disease. Front Neurol, 2022, 13: 1029669.
[14] Roy S, Ghosh S, Ray J, et al. Missing heritability of Wilson disease: a search for the uncharacterized mutations. Mamm Genome, 2022,53(2):212-216.
[15] Petters J, Volkner C, Krohn S, et al.Generation of two induced pluripotent stem cell lines from a female adult homozygous for the Wilson disease associated atp7b variant p.h1069q (akosi008-a) and a healthy control (akosi009-a). Stem Cell Res, 2020, 49: 102079.
[16] Pfeiffer RF. Diagnosing Wilson's disease under the sword of damocles. Neurol Neurochir Pol, 2020, 54(5): 364-365.
[17] Brown RS, Jr. An update on the future of Wilson disease management. Prim Care Companion CNS Disord, 2022, 24(6):814-819.
[18] Zhi Y, Sun Y, Jiao Y, et al. Hr-ms based untargeted lipidomics reveals characteristic lipid signatures of Wilson's disease. Front Pharmacol, 2021, 12: 754185.
[19] Cai N, Lin J, Zhu J. Reversible diffusion-weighted imaging high intensity signal in Wilson disease. Neurology, 2022,67(6):617-621.
[20] Davis S, Chag J, Rohatgi S, et al. Catatonia: a rare presentation of Wilson's disease. Ind Psychiatry J, 2021, 30(Suppl 1): S325-S327.

肝豆状核变性、非酒精性脂肪性肝病和自身免疫性肝炎儿童肝组织超微结构变化特征^*

Hepatic ultrastructural features of paediatric Wilson’s disease, NAFLD and autoimmune hepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邱丽瑛, 王迎春. 非酒精性脂肪性肝病与肠道微生态[J]. 实用肝脏病杂志, 2023, 26(3): 308-312.
[2]	王凌云, 周永健. 肠道菌群与自身免疫性肝炎研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 317-319.
[3]	湛栖睿, 段太美, 闫洁. 非酒精性脂肪性肝病患者血清淀粉样蛋白A、血浆血红素氧合酶1和骨形成蛋白9水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(3): 348-351.
[4]	赵玲玲, 王贝贝, 姚勇利, 郑有花, 李亚楠. T2DM合并非酒精性脂肪性肝病伴进展性肝纤维化患者血清抵抗素和TyG指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(3): 356-359.
[5]	朱琳, 陈洋, 杨青, 刘俊启. 超声弹性成像评估自身免疫性肝炎患者肝纤维化分期价值分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 360-363.
[6]	郭银燕, 岳枝, 盖晓冬, 冯艳红, 张杰东. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征患者临床和肝组织病理学特征分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 372-375.
[7]	苏佩华, 宋枚芳, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病与肝细胞癌[J]. 实用肝脏病杂志, 2023, 26(3): 445-448.
[8]	魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.
[9]	范明芳, 田瑛, 周倩, 接贵涛, 刘淑芳. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清RBP4和SREBP-1c水平变化分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 185-188.
[10]	郝蕾, 高卫东, 胡娟娟, 张琳, 邢亚恒. 非酒精性脂肪性肝病患者血清脂联素、维生素D和载脂蛋白B水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 189-192.
[11]	方颖, 金家东, 汪芾, 周达. 新冠疫情期间情绪对非酒精性脂肪性肝病患者血生化指标的影响^*[J]. 实用肝脏病杂志, 2023, 26(2): 193-196.
[12]	刘岗, 张浩, 胡峻. 非酒精性脂肪性肝病患者血清miR-183-5p和miR-96-5p水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 197-201.
[13]	李潇萌, 吴少玉, 王媛媛. 非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 202-205.
[14]	凌佳慧, 倪美鑫, 韩黎黎, 卫栋萍, 戴轶伟, 陈婷婷. 异甘草酸镁治疗自身免疫性肝炎患者血清细胞因子水平变化^*[J]. 实用肝脏病杂志, 2023, 26(2): 214-217.
[15]	王焱, 周静, 韩军. 自身免疫性肝炎和药物性肝损伤患者临床病理特征分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 218-221.